Treatment of Sindbis Virus-Infected Neurons with Antibody to E2 Alters Synthesis of Complete and nsP1-Expressing Defective Viral RNAs

Figures

• 

  FIG 1. SINV RNA forms. (A) Schematic diagram of SINV RNA replication and the forms of SINV RNA made from each type of template strand. “gRNA” represents genomic RNA, “sgRNA” represents subgenomic RNA, and “DVG” represents the defective viral genome. (B) Table of the different SINV RNA forms indicating their sense, genome nucleotide composition, polyadenylation status, and translation to proteins.

• 

  FIG 2. Nanopore sequencing of SINV-infected differentiated AP-7 cells with or without anti-E2 antibody treatment. Differentiated AP-7 cells were infected with SINV (MOI of 10) and mock treated or treated with anti-E2 antibody (5 μg/mL) 4 h after infection. At 24, 48, and 72 h after infection, total intracellular RNA was collected in triplicate, enriched for poly(A), directly sequenced via nanopore sequencing, and aligned to the rat or SINV genome. (A) Proportion of RNA reads that align to the rat versus SINV genome. Proportions indicate the number of rat or SINV reads divided by the total number of RNA reads at each time point for mock-infected cells. The mock-infected 24-h sample is indicated in purple. (All mock time points had 0 SINV-aligned reads.) SINV-infected no-antibody-treatment samples are indicated in orange, and SINV-infected antibody-treated samples are indicated in green. Each dot indicates a different biological replicate. (B) Averaged sequence coverage of SINV-aligned RNA reads. Coverage plots indicate relative sequencing depth normalized to run yield across the SINV genome with (green) or without (orange) antibody treatment at 24, 48, and 72 h after infection. Coverage…

• 

  FIG 3. Anti-E2 antibody increases production of SINV genomic RNA and decreases production of subgenomic RNA. Analysis of newly synthesized viral RNA. Differentiated AP-7 cells were infected with SINV (MOI of 10) and treated with anti-E2 antibody (5 μg/mL) at 4 h after infection. At the indicated time points, cells were labeled with 20 μCi/mL [3H]uridine in the presence of dactinomycin (1 μg/mL) for 2 h. (A) Representative assessment of radioactive viral RNA synthesis by agarose-formaldehyde gel and autoradiography. (Top) Long exposure; (bottom) short exposure of the same gel. (B) Densities of labeled genomic RNA (gRNA [left]) and subgenomic RNA (sgRNA [right]) normalized to SINV-infected, untreated cells at 12 h; (C) ratio of relative subgenomic RNA to genomic RNA density; (D) ratios of qRT-PCR-quantified biotin-captured 5-ethynyl uridine-labeled nascent subgenomic RNA to genomic RNA in SINV-infected dAP-7 cells with and without antibody treatment. Data from three independent experiments are presented as mean ± SD. **, P < 0.01; ****, P < 0.0001.

• 

  FIG 4. Antibody treatment increases SINV genomic RNA and decreases nsP1 defective viral genome RNA levels in dAP-7 cells. (A and B) Differentiated AP-7 cells were infected with SINV (MOI of 10) and treated with anti-E2 antibody (5 μg/mL) or medium (mock) at 4 h after infection. At the indicated time points, total cellular RNA lysates were collected. (A) Semiquantitative RT-PCR for SINV RNA using primers against the 5′ and 3′ ends of the SINV genome (SV-171F, SV-11655R). “gRNA” represents full-length SINV genomic RNA, and “DVG” represents the nsP1 defective viral genome. Asterisks indicate PCR bands excised for DNA extraction and Sanger sequencing. (B) SINV genome sequence alignment of the two defective viral genome sequences identified. (C and D) Differentiated AP-7 cells (dAP-7), undifferentiated cycling AP-7 cells (cAP-7), and BHK-21 cells were infected with SINV (MOI of 10) and treated with medium (mock) or anti-E2 antibody (5 μg/mL) at 4 h after infection. Twenty-four hours after infection, total cellular RNA was reverse transcribed to cDNA for qRT-PCR analysis of nsP1 defective viral genome levels. (C) Primer design used for qRT-PCR assay. Primers for the nsP1 defective viral…

• 

  FIG 5. The nsP1 defective viral genome is packaged and released into viral particles. Differentiated AP-7 cells were infected with SINV (MOI of 10) and treated with medium (mock) or anti-E2 antibody (5 μg/mL) at 4 h after infection. Eighteen hours after infection, RNA from the cells and supernatant fluid was collected. (A) RNA was extracted from the cellular and supernatant samples. RT-PCR analysis for SINV genomic RNA (gRNA) and nsP1 defective viral genome RNA (DVG) was performed. “NTC” represents the no-template control. (B) RNase A protection assay. Culture supernatant was treated with RNase A (10 μg/mL) to digest all nonencapsidated RNAs (+B [before RNA extraction]) or untreated (−). Following RNase treatment, RNA was extracted from the supernatant and reverse transcribed for RT-PCR analysis of nsP1 defective genome RNA (dgRNA). As a positive control for RNase activity, extracted RNA was also treated with RNase A under the same conditions (+A [after RNA extraction]).

• 

  FIG 6. The nsP1 defective viral genome RNA can be translated, and expression is associated with increased SINV RNA capping efficiency. (A) The shorter nsP1 defective viral genome RNA (subDVG) was cloned into the pcDNA3.1 DNA expression vector and in vitro transcribed to RNA (dvgRNA). The RNA was capped and polyadenylated in vitro, purified, and transfected into uninfected undifferentiated AP-7 cells (dvgRNA-AAA). As controls, pTE (complete SINV plasmid) and unpolyadenylated defective viral genome RNA (dvgRNA−) were also transfected. Twenty-four hours after transfection, lysates were collected and assessed by immunoblot probing with a polyclonal antibody against SINV nsP1. (B) Proportion of capped genomes in virus particles released from untreated and antibody-treated SINV-infected dAP-7 cells. Differentiated AP-7 cells were infected with SINV (MOI of 10) and treated with medium (mock) or anti-E2 antibody (5 μg/mL) 4 h after infection. Twenty-four hours after infection, virus particles were purified from the supernatant fluid by ultracentrifugation and viral RNA was extracted and treated with XRN-1 exoribonuclease to degrade noncapped RNAs (XRN +) or left untreated (XRN −). Following…

• 

  FIG 7. Model of nsP1 defective genome proviral activity (above) and interactions with antiviral anti-E2 antibody (below). nsP1 DVG expression results in increased production of SINV nsP1 protein and improved SINV RNA capping efficiency. The nsP1 DVG is packaged into defective interfering particles (DIPs) that can spread from cell to cell and replicate during coinfection with wild-type virus. Anti-E2 antibody suppresses viral RNA transcription and particularly affects SINV sgRNA and nsP1 DVG production. Anti-E2 antibody also inhibits viral and DIP budding by direct binding of surface E2. Inhibition of spread of the nsP1 DVG by inhibition of budding or neutralization contributes to overall decreased viral replication by decreasing production of nsP1 protein and decreasing SINV RNA capping efficiency during late infection.